Journal of Clinical Toxicology
Open Access
ISSN: 2161-0495
+44 1478 350008
ISSN: 2161-0495
+44 1478 350008
Fatemeh Namvaran
Posters: J Clinic Toxicol
T he peroxisome proliferator-activated receptor γ (PPARγ) has important effects in insulin sensitivity, obesity and diabetes. Thiozolidendions improve insulin sensitivity by activating the PPARγ. Based on strong evidences, we expect increased fracture risk, and delayed fracture healing through thiozolidendions treatment. Our aim is to study any association between variation in bone biochemical markers and single nucleotide polymorphism (SNP) in PPARγ (pro12 Ala) and investigating if these genetic variant affect bone turn over markers in an Iranian diabetic population before and after treatment with pioglitazone. A total of 101 patients (T2D) were treated for 12 weeks with pioglitazone (15 mg/day). Bone Biological markers, osteocalcin and C-terminal telopeptide of type 1 collagen (ICTP) were measured before and after pioglitazone therapy. We genotyped 128 non- diabetic controls and 101 Type 2 diabetic patients as well. Pro12Ala polymorphism in PPARγ was done by Real Time PCR using TaqMan assay. There were statistically-significant differences in allele frequencies of Pro12Ala comparing controls with Type 2 diabetic subjects. Ala frequency was 7% vs. 3 %, p = 0.036, and genotypic frequencies of Pro/Ala were 5.94% vs 14.06%, p value = 0.04. There were significant differences in bone biological markers before and after pioglitazone therapy. Our findings could not reach to significant association between this polymorphism and bone turn over markers after pioglitazone treatment. We found that pioglitazone treatment caused significant changes in bone biological markers after treatment
Fatemeh Namvaran has completed his Ph.D at the age of 30 years from Tehran University of Medical Sciences, College of Medicine. She is working with Transplant Research Center, Shiraz University of Medical Sciences. She has published 10 papers in reputed journals